2 active not recruiting, 1 completed. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Squamous Cell Carcinoma of Unknown Primary: new trials by email Literature Review of Squamous Cell Carcinoma of Unknown Primary trials Research Report on Squamous Cell Carcinoma of Unknown Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cemiplimab, Paclitaxel - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Marcelo Bonomi | 46 | 2021-11-30 | 2026-06-25 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 196 | 2018-04-03 | 2026-08-27 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-11-12 |
Hypopharyngeal Neoplasms (2) · Laryngeal Neoplasms (2) · Mouth Neoplasms (2) · Oropharyngeal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma, Papillary (1) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Basosquamous (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Signet Ring Cell (1) · Eccrine Porocarcinoma (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Carcinoma (2) · Carcinoma, Squamous Cell (2) · Head and Neck Neoplasms (2) · Laryngeal Diseases (2) · Mouth Diseases (2) · Otorhinolaryngologic Diseases (2) · Otorhinolaryngologic Neoplasms (2) · Pharyngeal Diseases (2) · Pharyngeal Neoplasms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2)
(225)Ac-DOTA-c(RGDyK) (1) · Biopsy (1) · Carboplatin (1) · Cetuximab (1) · Disulfides (1) · Immunoglobulin G (1) · Nivolumab (1) · Paclitaxel (1) · Radiotherapy, Intensity-Modulated (1) · Specimen Handling (1) · Taxes (1) · cemiplimab (1) · durvalumab (1) · talimogene laherparepvec (1)
National Cancer Institute (NCI) (2) · Marcelo Bonomi (1)
United States (3) · Canada (1)
Loren K Mell (1) · Marcelo R Bonomi, MD (1)
U10CA180868 (1), UM1CA186709 (1), UM1CA186716 (1)